SHARE

Pharmacyte Biotech Inc (OTCMKTS:PMCB), a leading clinical stage biotech company, is pleased to announce that its diabetes and cancer treatments have got featured on Discovery Channel. As per the reports, this broadcast helped the company spreading information about its technology and treatments at a national level.

Insights On The Matter:

The company focuses mainly on the development of targeted treatments for cancer and diabetes with the help of its trademark live-cell encapsulation technology named Cell-in-a-Box. Its story aired on ION Network and Discovery Channel’s news magazine series ‘NewsWatch.’ It’s one of the leading sources for breaking technology, consumer, travel, entertainment and health news. The news series has been successfully running since 1990 and offering world-class insights to people from all over the country.

NewsWatch office is based in Washington area and gets aired national wide. People from different markets can virtually use this platform to receive excellent news belonging to different sectors. Reports claim that each edition of NewsWatch taps more than 96 million households in the United States. So far, more than 700 million people have had access to this news series, making it one of the most sought after independently produced magazines on the digital space.

The Pharmacyte Biotech story was aired in ‘HealthWatch’ segment of NewsWatch.

The senior management of the company is delighted to share this update and hopes that Pharmacyte Biotech will continue getting such opportunities in the future as well. According to Kenneth L. Waggoner, Chief Executive Officer, Pharmacyte Biotech Inc (OTCMKTS:PMCB), it’s a great opportunity for the company to share such quality information with the nationwide audience.

The management team grabbed the opportunity with both hands when NewsWatch staff asked if it would like to share news regarding its technology and treatments targeting diabetes and cancer with the nation. The prime objective of the company is to help people in any possible way, and it was one such decision.

LEAVE A REPLY